JP7789016B2 - 癌治療における標的化不能ｋｒａの標的分解のための新規の小分子 - Google Patents
癌治療における標的化不能ｋｒａの標的分解のための新規の小分子Info
- Publication number
- JP7789016B2 JP7789016B2 JP2022574452A JP2022574452A JP7789016B2 JP 7789016 B2 JP7789016 B2 JP 7789016B2 JP 2022574452 A JP2022574452 A JP 2022574452A JP 2022574452 A JP2022574452 A JP 2022574452A JP 7789016 B2 JP7789016 B2 JP 7789016B2
- Authority
- JP
- Japan
- Prior art keywords
- compound
- kras
- cancer
- cell
- mutant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN202041023434 | 2020-06-04 | ||
| IN202041023434 | 2020-06-04 | ||
| PCT/IB2021/054591 WO2021245499A1 (en) | 2020-06-04 | 2021-05-26 | Novel small molecules for targeted degradation of untargetable kras in cancer therapy |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023529354A JP2023529354A (ja) | 2023-07-10 |
| JP2023529354A5 JP2023529354A5 (https=) | 2024-06-03 |
| JP7789016B2 true JP7789016B2 (ja) | 2025-12-19 |
Family
ID=78830675
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022574452A Active JP7789016B2 (ja) | 2020-06-04 | 2021-05-26 | 癌治療における標的化不能ｋｒａの標的分解のための新規の小分子 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230202981A1 (https=) |
| EP (1) | EP4161511B1 (https=) |
| JP (1) | JP7789016B2 (https=) |
| KR (1) | KR20230019937A (https=) |
| CN (2) | CN115768427B (https=) |
| AU (1) | AU2021284517A1 (https=) |
| BR (1) | BR112022024300A2 (https=) |
| CA (1) | CA3180686A1 (https=) |
| IL (1) | IL298672A (https=) |
| MX (1) | MX2022015253A (https=) |
| WO (1) | WO2021245499A1 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019217307A1 (en) | 2018-05-07 | 2019-11-14 | Mirati Therapeutics, Inc. | Kras g12c inhibitors |
| EA202190749A1 (ru) | 2018-09-10 | 2021-07-09 | Мирати Терапьютикс, Инк. | Способы комбинированной терапии |
| EP3849535A4 (en) | 2018-09-10 | 2022-06-29 | Mirati Therapeutics, Inc. | Combination therapies |
| JP2022500385A (ja) | 2018-09-10 | 2022-01-04 | ミラティ セラピューティクス， インコーポレイテッド | 組み合わせ療法 |
| EP3849537B1 (en) | 2018-09-10 | 2024-10-23 | Mirati Therapeutics, Inc. | Combination therapies |
| MX2021002804A (es) | 2018-12-05 | 2021-07-15 | Mirati Therapeutics Inc | Terapias de combinacion. |
| EP3908283A4 (en) | 2019-01-10 | 2022-10-12 | Mirati Therapeutics, Inc. | KRAS G12C INHIBITORS |
| MX2022002465A (es) | 2019-08-29 | 2022-05-19 | Mirati Therapeutics Inc | Inhibidores de kras g12d. |
| WO2021061749A1 (en) | 2019-09-24 | 2021-04-01 | Mirati Therapeutics, Inc. | Combination therapies |
| PH12022551513A1 (en) | 2019-12-20 | 2023-04-24 | Mirati Therapeutics Inc | Sos1 inhibitors |
| EP4210833A4 (en) | 2020-09-11 | 2024-09-11 | Mirati Therapeutics, Inc. | CRYSTALLINE FORMS OF A KRAS G12C INHIBITOR |
| JP2023553492A (ja) | 2020-12-15 | 2023-12-21 | ミラティ セラピューティクス， インコーポレイテッド | アザキナゾリン汎ＫＲａｓ阻害剤 |
| EP4262803A4 (en) | 2020-12-16 | 2025-03-12 | Mirati Therapeutics, Inc. | Tetrahydropyridopyrimidine pan-kras inhibitors |
| WO2025083563A1 (en) * | 2023-10-18 | 2025-04-24 | Pillai Universal Llc | Effective therapeutic small-molecule inhibitors for metastatic cancer |
| WO2025083561A1 (en) * | 2023-10-18 | 2025-04-24 | Pillai Universal Llc | Novel lead small molecule inhibitors on undruggable target towards anticancer activity |
| WO2025083564A1 (en) * | 2023-10-18 | 2025-04-24 | Pillai Universal Llc | Novel small molecule degrader as a potential anticancer |
| WO2025083568A1 (en) * | 2023-10-18 | 2025-04-24 | Pillai Universal Llc | Novel small-molecule protein kinase inhibitors for implications in cancer treatment |
| WO2025083570A1 (en) * | 2023-10-18 | 2025-04-24 | Pillai Universal Llc | Novel small-molecule agents in overcoming tumor regression in cancers |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004510697A (ja) | 2000-05-22 | 2004-04-08 | アベンティス・ファーマスーティカルズ・インコーポレイテツド | トリプターゼ阻害剤として使用するためのアリールメチルアミン誘導体 |
| JP2005507423A (ja) | 2001-11-01 | 2005-03-17 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | グリコーゲン合成酵素キナーゼ３ベータ阻害剤（ｇｓｋ３阻害剤）としてのヘテロアリールアミン |
| WO2007075896A2 (en) | 2005-12-22 | 2007-07-05 | Kemia, Inc. | Heterocyclic cytokine inhibitors |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| OA12274A (en) * | 2000-05-22 | 2006-05-09 | Aventis Pharma Inc | Arylmethylamine derivatives for use as tryptase inhibitors. |
| JP2013525308A (ja) * | 2010-04-16 | 2013-06-20 | キュリス，インコーポレイテッド | Ｋ−ｒａｓ変異を有する癌の治療 |
| US20190284149A1 (en) * | 2014-09-12 | 2019-09-19 | Ariagen, Inc. | Aryl hydrocarbon receptor modulator |
| CN106317055A (zh) * | 2015-07-02 | 2017-01-11 | 中国科学院上海药物研究所 | 一类具有激酶抑制活性的化合物、制备方法和用途 |
| WO2018140513A1 (en) * | 2017-01-26 | 2018-08-02 | Araxes Pharma Llc | 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer |
| CN110885332B (zh) * | 2019-12-06 | 2022-03-18 | 中国人民解放军第二军医大学 | 一种PDEδ蛋白降解靶向嵌合体及其制备方法和应用 |
-
2021
- 2021-05-26 US US18/008,332 patent/US20230202981A1/en active Pending
- 2021-05-26 BR BR112022024300A patent/BR112022024300A2/pt unknown
- 2021-05-26 CA CA3180686A patent/CA3180686A1/en active Pending
- 2021-05-26 IL IL298672A patent/IL298672A/en unknown
- 2021-05-26 MX MX2022015253A patent/MX2022015253A/es unknown
- 2021-05-26 KR KR1020237000112A patent/KR20230019937A/ko active Pending
- 2021-05-26 CN CN202180049321.9A patent/CN115768427B/zh active Active
- 2021-05-26 CN CN202510275737.2A patent/CN120208921A/zh active Pending
- 2021-05-26 JP JP2022574452A patent/JP7789016B2/ja active Active
- 2021-05-26 WO PCT/IB2021/054591 patent/WO2021245499A1/en not_active Ceased
- 2021-05-26 AU AU2021284517A patent/AU2021284517A1/en active Pending
- 2021-05-26 EP EP21817859.8A patent/EP4161511B1/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004510697A (ja) | 2000-05-22 | 2004-04-08 | アベンティス・ファーマスーティカルズ・インコーポレイテツド | トリプターゼ阻害剤として使用するためのアリールメチルアミン誘導体 |
| JP2005507423A (ja) | 2001-11-01 | 2005-03-17 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | グリコーゲン合成酵素キナーゼ３ベータ阻害剤（ｇｓｋ３阻害剤）としてのヘテロアリールアミン |
| WO2007075896A2 (en) | 2005-12-22 | 2007-07-05 | Kemia, Inc. | Heterocyclic cytokine inhibitors |
Non-Patent Citations (2)
| Title |
|---|
| PUBCHEM SID:245134309，2015年03月17日 |
| PUBCHEM SID:374716721，2018年06月23日 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP4161511A1 (en) | 2023-04-12 |
| KR20230019937A (ko) | 2023-02-09 |
| MX2022015253A (es) | 2023-03-14 |
| IL298672A (en) | 2023-01-01 |
| BR112022024300A2 (pt) | 2023-01-24 |
| TW202210465A (zh) | 2022-03-16 |
| CN115768427B (zh) | 2025-03-28 |
| WO2021245499A1 (en) | 2021-12-09 |
| CN115768427A (zh) | 2023-03-07 |
| EP4161511B1 (en) | 2026-04-29 |
| AU2021284517A1 (en) | 2023-01-05 |
| JP2023529354A (ja) | 2023-07-10 |
| EP4161511A4 (en) | 2024-07-17 |
| CN120208921A (zh) | 2025-06-27 |
| US20230202981A1 (en) | 2023-06-29 |
| CA3180686A1 (en) | 2021-12-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7789016B2 (ja) | 癌治療における標的化不能ｋｒａの標的分解のための新規の小分子 | |
| JP7123806B2 (ja) | 静止細胞標的化およびｅｇｆｒ阻害剤を用いた新生物の処置のための組み合わせ | |
| WO2016069392A1 (en) | Administration of ubiquitin-activating enzyme inhibitor and chemotherapeutic agents | |
| JP5078885B2 (ja) | Ｆｌｔ３阻害剤とファルネシル転移酵素阻害剤を用いたｆｌｔ３キナーゼの相乗的モジュレーション | |
| KR20140096375A (ko) | 항종양제의 효과 증강제 | |
| CN107666906A (zh) | 用于治疗癌症的方法 | |
| KR20080028919A (ko) | 티에노피리미딘 및 티에노피리딘 키나제 조절제를 사용한ｆｌｔ３ 키나제의 상승적 조절 | |
| CA2837042C (en) | A synergistic pharmaceutical combination for the treatment of squamous cell carcinoma of head and neck | |
| KR20080004495A (ko) | 암을 치료하기 위한 조합물, 방법 및 조성물 | |
| CN107708700A (zh) | 用于治疗癌症的方法 | |
| JP6373252B2 (ja) | オーロラキナーゼ阻害薬を使用する癌の治療方法 | |
| CN107820426A (zh) | 用于治疗癌症的方法 | |
| TWI916370B (zh) | 用於在癌症治療中對不可標定之kras進行降解標定之新穎小分子 | |
| EP4637769A1 (en) | Methods of treating advanced solid tumors | |
| RU2839932C1 (ru) | Новые малые молекулы для целенаправленного расщепления не поддающегося целенаправленному воздействию kras в терапии рака | |
| JP7513286B2 (ja) | 化学療法難治性がんの治療のための新しい併用薬方法 | |
| KR102436875B1 (ko) | Pi3 키나아제 억제제 및 bcl-2 억제제를 포함하는 조성물 | |
| AU2016296997A1 (en) | Chlorobenzene substituted azaaryl compounds | |
| CN111718328A (zh) | 4-甲基-1h-二芳基吡唑类衍生物在制备抗肿瘤药物中的用途 | |
| Bandivadekar et al. | Cdk 4/6 inhibitors revolutionized breast cancer therapy | |
| Greco | Synthesis and biological evaluation of pyrazolo [3, 4-d] pyrimidine derivatives active as SGK1, Fyn and Src kinases inhibitors | |
| WO2026006342A1 (en) | Direct-binding dual inhibitors of hypoxia-inducible factor 1 (hif-1) and hif-2 | |
| TW201605449A (zh) | 馬賽替尼治療結腸直腸癌的用途 | |
| JP2025539347A (ja) | Ｋｒａｓ阻害剤とｓｈｐ２阻害剤とを含む併用療法 | |
| HK40047114A (en) | New combination solution for treating chemotherapy refractory cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240524 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20240524 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20250423 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20250428 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250428 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20250728 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250929 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20251112 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20251209 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7789016 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |